AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22487159 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% VO(2peak) for 30 min (HIGH)
Number of subjects: 10
Study 22487159 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% VO(2peak) for 30 min (MOD)
Number of subjects: 10
Study 22487159 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% VO(2peak) for 60 min (MOD(L))
Number of subjects: 10
Study 20480800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 0
Study 20480800 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.3% gel
Number of subjects: 0
Study 18823201 — intervention group
Group type: EXPERIMENTAL
Intervention: Withheld action plan based on identity of a stimulus (Experiment 1)
Number of subjects: 0
Study 18823201 — intervention group
Group type: EXPERIMENTAL
Intervention: Withheld action plan based on identity of a stimulus (Experiment 2)
Number of subjects: 0
Study 18823201 — intervention group
Group type: EXPERIMENTAL
Intervention: Withheld action plan based on identity of a stimulus (Experiment 3)
Number of subjects: 0
Study 15661475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation, 60 mg retinol equivalent every 3 months
Number of subjects: 181
Study 15661475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 15661475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 181
Study 12905653 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 30
Study 12905653 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 30
Study 10069275 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of sufentanil (3.6 microg/kg/h) and midazolam (0.08 mg/kg/h)
Number of subjects: 30
Study 10069275 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of sufentanil (2 microg/kg) and midazolam (0.03 mg/kg)
Number of subjects: 30
Study 10069275 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of sufentanil and midazolam
Number of subjects: 30
Study 10069275 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of sufentanil and midazolam
Number of subjects: 30
Study 10069275 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration
Number of subjects: 30
Study 10069275 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion
Number of subjects: 30
Study 10069275 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion and bolus administration
Number of subjects: 30
Study 7723338 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 18
Study 7723338 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 18
Study 2033418 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (pilot protocol POG 8340)
Number of subjects: 116
Study 2033418 — intervention group
Group type: EXPERIMENTAL
Intervention: Any transplant (not specified)
Number of subjects: 116
Study 2033418 — intervention group
Group type: COMPARATOR
Intervention: Surgery plus conventional chemotherapy (POG 8441)
Number of subjects: 116
Study 7315207 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% metoprolol eye drops
Number of subjects: 0
Study 7315207 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol eye drops
Number of subjects: 0
Study 31091292 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-bias language condition
Number of subjects: 4
Study 31091292 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluation instrument
Number of subjects: 4
Study 25822106 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO) plus 1-day dexamethasone (DEX)
Number of subjects: 35
Study 25822106 — intervention group
Group type: COMPARATOR
Intervention: Fosaprepitant (FAPR), granisetron (GRAN), and DEX
Number of subjects: 35
Study 21054600 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's milk
Number of subjects: 120
Study 21054600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 120
Study 21054600 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier
Number of subjects: 120
Study 21054600 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 19701509 — intervention group
Group type: EXPERIMENTAL
Intervention: ozone + Clearfil Protect Bond
Number of subjects: 136
Study 19701509 — intervention group
Group type: EXPERIMENTAL
Intervention: ozone + Xeno III
Number of subjects: 136
Study 19701509 — intervention group
Group type: COMPARATOR
Intervention: Clearfil Protect Bond
Number of subjects: 136
Study 19701509 — intervention group
Group type: COMPARATOR
Intervention: Xeno III
Number of subjects: 136
Study 19701509 — intervention group
Group type: EXPERIMENTAL
Intervention: ozone + Clearfil Protect Bond (dentin)
Number of subjects: 136
Study 19701509 — intervention group
Group type: EXPERIMENTAL
Intervention: ozone + Xeno III (dentin)
Number of subjects: 136
Study 19701509 — intervention group
Group type: COMPARATOR
Intervention: Clearfil Protect Bond (dentin)
Number of subjects: 136
Study 19701509 — intervention group
Group type: COMPARATOR
Intervention: Xeno III (dentin)
Number of subjects: 136
Study 17760696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing lotion containing tamarind fruit extract with 2% (w/w) tartaric acid
Number of subjects: 15
Study 17760696 — intervention group
Group type: COMPARATOR
Intervention: Placebo product
Number of subjects: 15
Study 17760696 — intervention group
Group type: COMPARATOR
Intervention: De-ionized water
Number of subjects: 15
Study 15061263 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (early 4 h imaging)
Number of subjects: 220
Study 15061263 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (early and delayed 24 h imaging)
Number of subjects: 220
Study 15061263 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (delayed imaging)
Number of subjects: 220
Study 15061263 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (early high uptake intensity)
Number of subjects: 220
Study 11475180 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F + P + S (1.0 microgram/kg fentanyl and 0.5 mg/kg propofol prior to induction)
Number of subjects: 120
Study 11475180 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F + S (1.0 microgram/kg fentanyl prior to induction)
Number of subjects: 120
Study 11475180 — intervention group
Group type: COMPARATOR
Intervention: Group S (8% sevoflurane only)
Number of subjects: 120
Study 11475180 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F + P + S
Number of subjects: 120
Study 9735664 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized columnar epithelium presence in patients with short segment columnar-lined esophagus
Number of subjects: 0
Study 9735664 — intervention group
Group type: COMPARATOR
Intervention: Specialized columnar epithelium presence in patients without columnar-lined esophagus
Number of subjects: 0
Study 8052871 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 day I, etoposide 140 mg/m2 days 1 through 3, and vincristine 1.4 mg/m2 days 1, 8, and 15 (CEV)
Number of subjects: 317
Study 8052871 — intervention group
Group type: COMPARATOR
Intervention: Etoposide 200 mg/m2 days 1 through 3 and vincristine 1.4 mg/m2 days 1 and 8 (EV)
Number of subjects: 317
Study 8052871 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/etoposide/vincristine (CEV)
Number of subjects: 317
Study 8052871 — intervention group
Group type: COMPARATOR
Intervention: Etoposide/vincristine (EV)
Number of subjects: 317
Study 1969017 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate and prostaglandin E1
Number of subjects: 0
Study 478206 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (two 10‐mg tablets t.i.d. before meals)
Number of subjects: 32
Study 478206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two 10‐mg tablets t.i.d. before meals)
Number of subjects: 32
Study 478206 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 32
Study 31816417 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered trials
Number of subjects: 625
Study 31816417 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospectively registered trials
Number of subjects: 625
Study 31816417 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials providing protocols
Number of subjects: 625
Study 31816417 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with larger enrollment numbers
Number of subjects: 625
Study 31816417 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with nonindustry funding
Number of subjects: 625
Study 30102389 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir for 6 months
Number of subjects: 38
Study 30102389 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 38
Study 28013058 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg compressions
Number of subjects: 13
Study 28013058 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 13
Study 25530265 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 300 mg day(‐1) intravenous monotherapy
Number of subjects: 17
Study 25530265 — intervention group
Group type: COMPARATOR
Intervention: Control monotherapy (lipid amphotericin B 5 mg kg(‐1) day(‐1), voriconazole 8 mg kg(‐1) day(‐1), or caspofungin 50 mg day(‐1))
Number of subjects: 17
Study 23113540 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine placental extract (PPE) for 24 weeks in climacteric women and 12 weeks in postmenopausal women with HT
Number of subjects: 66
Study 23113540 — intervention group
Group type: COMPARATOR
Intervention: Toki-shakuyaku-san (TJ23; 7.5 g/day)
Number of subjects: 66
Study 21285125 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 0.7-1.4 mg/kg/day
Number of subjects: 30
Study 21285125 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Amlodipine 0.1-0.2 mg/kg/day up to 5 mg/day
Number of subjects: 30
Study 19739064 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and child welfare intervention
Number of subjects: 25
Study 19739064 — intervention group
Group type: COMPARATOR
Intervention: Training
Number of subjects: 25
Study 17983260 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-use ethinylestradiol/levonorgestrel 20μg/90μg
Number of subjects: 2134
Study 15145879 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after atrial correction for TGA
Number of subjects: 27
Study 11564203 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 80
Study 11564203 — intervention group
Group type: COMPARATOR
Intervention: Textbook (text group)
Number of subjects: 80
Study 11564203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CAI and text)
Number of subjects: 80
Study 9521830 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental memory tests for explicit information in DID subjects
Number of subjects: 4
Study 9521830 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental memory tests for implicit information in DID subjects
Number of subjects: 4
Study 7820974 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic inhibition with propranolol
Number of subjects: 7
Study 3393382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (0.001 mg/kg) administered 90 minutes before exercise test
Number of subjects: 16
Study 3393382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (0.001 mg/kg) administered 300 minutes before exercise test
Number of subjects: 16
Study 3393382 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.12 mg/kg) administered 90 minutes before exercise test
Number of subjects: 16
Study 3393382 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.12 mg/kg) administered 300 minutes before exercise test
Number of subjects: 16
Study 31286656 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm I: Portable play equipment added to the school environment
Number of subjects: 97
Study 31286656 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm II: Portable play equipment plus PA education for staff and children
Number of subjects: 97
Study 29096833 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Lp(a) apheresis
Number of subjects: 15
Study 29096833 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy (Control)
Number of subjects: 15
Study 26583658 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh-augmented hiatoplasty with cardiophrenicopexy (LMAH-C)
Number of subjects: 90
Study 26583658 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 90
Study 26583658 — intervention group
Group type: EXPERIMENTAL
Intervention: LMAH-C
Number of subjects: 90
Study 26583658 — intervention group
Group type: COMPARATOR
Intervention: LNF
Number of subjects: 90
Study 23537979 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 111
Study 23537979 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 111
Study 21668938 — intervention group
Group type: EXPERIMENTAL
Intervention: C6 injection
Number of subjects: 60
Study 21668938 — intervention group
Group type: COMPARATOR
Intervention: C5 injection
Number of subjects: 60
Study 19840639 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Obturators (PTO)
Number of subjects: 8
Study 19840639 — intervention group
Group type: COMPARATOR
Intervention: System‐B/Calamus (SBC)
Number of subjects: 8
Study 17040590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C applied topically post-operatively in FESS
Number of subjects: 30
Study 17040590 — intervention group
Group type: COMPARATOR
Intervention: Control side (no mitomycin C)
Number of subjects: 30
Study 15319017 — intervention group
Group type: EXPERIMENTAL
Intervention: BID MPH for 7 days a week
Number of subjects: 40
Study 15319017 — intervention group
Group type: COMPARATOR
Intervention: BID MPH on weekdays and placebo on weekends
Number of subjects: 40
Study 15319017 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of MPH on weekends
Number of subjects: 40
Study 10764680 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral estradiol valerate (2 mg/d)
Number of subjects: 79
Study 10764680 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol gel (1 mg/d)
Number of subjects: 79
Study 10764680 — intervention group
Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 79
Study 9331308 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intravenous (IV) hydration after tonsillectomy
Number of subjects: 100
Study 9331308 — intervention group
Group type: COMPARATOR
Intervention: No home intravenous (IV) hydration after tonsillectomy
Number of subjects: 100
Study 8453962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol taken orally at 08.00 h
Number of subjects: 6
Study 8453962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol taken orally at 14.00 h
Number of subjects: 6
Study 8453962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol taken orally at 20.00 h
Number of subjects: 6
Study 8453962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol taken orally at 02.00 h
Number of subjects: 6
Study 2429834 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade
Number of subjects: 60
Study 2429834 — intervention group
Group type: COMPARATOR
Intervention: Neurolept anaesthesia
Number of subjects: 60
Study 31983371 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min) combined with speech-language therapy
Number of subjects: 10
Study 31983371 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with speech-language therapy
Number of subjects: 10
Study 30373688 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item sleep quality scale (SQS)
Number of subjects: 721
Study 27524671 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group with monthly bisphosphonate regimen
Number of subjects: 979
Study 27524671 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group with weekly bisphosphonate regimen
Number of subjects: 979
Study 27524671 — intervention group
Group type: COMPARATOR
Intervention: Control group with monthly bisphosphonate regimen
Number of subjects: 979
Study 27524671 — intervention group
Group type: COMPARATOR
Intervention: Control group with weekly bisphosphonate regimen
Number of subjects: 979
Study 27524671 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly regimen
Number of subjects: 979
Study 27524671 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly regimen
Number of subjects: 979
Study 24888479 — intervention group
Group type: EXPERIMENTAL
Intervention: WELLFOCUS PPT (11-session group therapy in addition to treatment as usual)
Number of subjects: 80
Study 24888479 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 80
Study 22876730 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity supports
Number of subjects: 8
Study 22876730 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral trunk supports
Number of subjects: 8
Study 22876730 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior pelvic belt
Number of subjects: 8
Study 22876730 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degree posterior seat tilt
Number of subjects: 8
Study 22876730 — intervention group
Group type: EXPERIMENTAL
Intervention: Various wheelchair configurations (conditions 1-6)
Number of subjects: 8
Study 20816546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen delivered via nasal cannula at 2 L per min for 7 days
Number of subjects: 239
Study 20816546 — intervention group
Group type: COMPARATOR
Intervention: Room air delivered via nasal cannula at 2 L per min for 7 days
Number of subjects: 239
Study 20816546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 239
Study 20816546 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 239
Study 18768106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour prolonged release
Number of subjects: 161
Study 18768106 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole immediate release
Number of subjects: 161
Study 15922813 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable dosing of salmeterol/fluticasone propionate (SAL/FP) 50/250 microg BID
Number of subjects: 688
Study 15922813 — intervention group
Group type: COMPARATOR
Intervention: Adjustable maintenance dosing of formoterol/budesonide (FOR/BUD) 6/200 microg BID
Number of subjects: 688
Study 15922813 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable dosing of SAL/FP
Number of subjects: 688
Study 15922813 — intervention group
Group type: COMPARATOR
Intervention: Adjustable maintenance dosing of FOR/BUD
Number of subjects: 688
Study 12890374 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox-driven beta(2)-agonist therapy (Berotec)
Number of subjects: 32
Study 12890374 — intervention group
Group type: COMPARATOR
Intervention: Compressed air-driven beta(2)-agonist therapy (Berotec)
Number of subjects: 32
Study 10545430 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg bFGF
Number of subjects: 24
Study 10545430 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg bFGF
Number of subjects: 24
Study 10545430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8886564 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA model assessment of insulin resistance (IR) and insulin secretion from fasting glucose and insulin concentrations.
Number of subjects: 1449
Study 8886564 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA model assessment of insulin secretion.
Number of subjects: 1449
Study 1886349 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (2 x 200 mg/day)
Number of subjects: 35
Study 1886349 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 35
Study 6682324 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 15 mg/day
Number of subjects: 49
Study 6682324 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 15 mg/day
Number of subjects: 49
Study 31060979 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2
Number of subjects: 105
Study 31060979 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 90 mg/m2
Number of subjects: 105
Study 31060979 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2 and 90 mg/m2
Number of subjects: 105
Study 29924696 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments (COMP)
Number of subjects: 32
Study 29924696 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 32
Study 29924696 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - active recovery only
Number of subjects: 32
Study 26832427 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit (HV)
Number of subjects: 7039
Study 26832427 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit + drop-in (HV+drop-in)
Number of subjects: 7039
Study 26832427 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison arm)
Number of subjects: 7039
Study 24387094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group decision-making intervention (participants made decisions about lounge refurbishment as a group)
Number of subjects: 36
Study 24387094 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (staff made decisions about lounge refurbishment)
Number of subjects: 36
Study 24387094 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no treatment)
Number of subjects: 36
Study 22000905 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% oral glucose solution (2 mL)
Number of subjects: 120
Study 22000905 — intervention group
Group type: COMPARATOR
Intervention: Oral sterile water (2 mL)
Number of subjects: 120
Study 19562632 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 15
Study 19562632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17437473 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated schedules of preexposure tissue culture rabies vaccines
Number of subjects: 96
Study 17437473 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mL intradermally at two sites on one day
Number of subjects: 96
Study 15136288 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Lay Health Mentoring
Number of subjects: 289